The effect of intravitreal dexamethasone implantation on diabetic macular edema refractory to anti-vascular endothelial growth factor treatment

ABSTRACT Purpose To evaluate the efficacy and safety of intravitreal dexamethasone (DEX) implantation for diabetic macular edema (DME) that proved unresponsive to previous anti-vascular endothelial growth factor (VEGF) treatment. Methods This prospective interventional study recruited 91 patients with refractory DME after previous anti-VEGF treatments in one or both eyes. All patients were followed up for at least 12 months. Best-corrected visual acuity (BCVA), central subfield thickness (CST) and macular volume were measured. Results Over the 12 months, a mean of 2.1 ± 0.8 DEX implantations were administered per eye; 26 eyes (28.9%) received 1 implantation, 31 (34.4%) received 2, and 34 (36.7%) received 3. BCVA was significantly improved in the first 6 months, from 54.8 to 59.5 letters. Both CST and macular volume decreased significantly after DEX implantation and maintained these improvements for at least 12 months. Subjects who needed the second DEX implantation had a greater number of prior anti-VEGF injections than did those who needed only one implantation (6.0 vs 3.0). Conclusions Two-thirds of refractory DME required less than two DEX implantations to maintain a dry macula for 12 months. Early switching to intravitreal DEX can be considered as the second-line therapeutic option, especially during the COVID-19 pandemic.

[1]  R. Rejdak,et al.  Delayed Intravitreal Anti-VEGF Therapy for Patients During the COVID-19 Lockdown: An Ethical Endeavor , 2021, Clinical ophthalmology.

[2]  R. Rejdak,et al.  Early impact of COVID-19 outbreak on eye care: Insights from EUROCOVCAT group , 2020, European journal of ophthalmology.

[3]  Grading Diabetic Retinopathy from Stereoscopic Color Fundus Photographs - An Extension of the Modified Airlie House Classification: ETDRS Report Number 10. , 2020, Ophthalmology.

[4]  N. Duru,et al.  COMPARISON OF INTRAVITREAL DEXAMETHASONE IMPLANT AND AFLIBERCEPT IN PATIENTS WITH TREATMENT-NAIVE DIABETIC MACULAR EDEMA WITH SEROUS RETINAL DETACHMENT. , 2020, Retina.

[5]  J. Chhablani,et al.  DEXAMETHASONE IMPLANT FOR DIABETIC MACULAR EDEMA IN NAIVE COMPARED WITH REFRACTORY EYES: The International Retina Group Real-Life 24-Month Multicenter Study. The IRGREL-DEX Study , 2019, Retina.

[6]  A. Ebneter,et al.  Repeated Dexamethasone Intravitreal Implant for the Treatment of Diabetic Macular Oedema Unresponsive to Anti-VEGF Therapy: Outcome and Predictive SD-OCT Features , 2018, Ophthalmologica.

[7]  A. Loewenstein,et al.  OCT Biomarkers as Functional Outcome Predictors in Diabetic Macular Edema Treated with Dexamethasone Implant. , 2017, Ophthalmology.

[8]  S. Kabanarou,et al.  Dexamethasone Intravitreal Implant in Diabetic Macular Edema: Real-Life Data from a Prospective Study and Predictive Factors for Visual Outcome , 2017, Diabetes Therapy.

[9]  N. Voirin,et al.  REAL-LIFE STUDY IN DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE IMPLANT: The Reldex Study , 2017, Retina.

[10]  A. Ho,et al.  Early and Long-Term Responses to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data. , 2016, American journal of ophthalmology.

[11]  Sanket U. Shah,et al.  PROSPECTIVE RANDOMIZED SUBJECT-MASKED STUDY OF INTRAVITREAL BEVACIZUMAB MONOTHERAPY VERSUS DEXAMETHASONE IMPLANT MONOTHERAPY IN THE TREATMENT OF PERSISTENT DIABETIC MACULAR EDEMA , 2016, Retina.

[12]  P. Romero-Aroca,et al.  What Is the Role of Retinal Barriers in Diabetic Macular Edema ? , 2016 .

[13]  C. Regillo,et al.  Predictors of Diabetic Macular Edema Treatment Frequency with Ranibizumab During the Open-Label Extension of the RIDE and RISE Trials. , 2016, Ophthalmology.

[14]  E. Souied,et al.  Assessment of the Real-Life Usage of Intravitreal Dexamethasone Implant in the Treatment of Chronic Diabetic Macular Edema in France. , 2016, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[15]  I. Aknin,et al.  Longitudinal Study of Sustained-Release Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema , 2016, Ophthalmologica.

[16]  J. F. Arevalo,et al.  INTRAVITREAL DEXAMETHASONE IMPLANT FOR THE TREATMENT OF REFRACTORY MACULAR EDEMA IN RETINAL VASCULAR DISEASES: Results of the KKESH International Collaborative Retina Study Group , 2016, Retina.

[17]  A. Loewenstein,et al.  Dexamethasone intravitreal implant in the treatment of diabetic macular edema , 2015, Clinical ophthalmology.

[18]  G. Querques,et al.  REPEATED INTRAVITREAL DEXAMETHASONE IMPLANT (OZURDEX) FOR DIABETIC MACULAR EDEMA , 2015, Retina.

[19]  E. Gusson,et al.  Dexamethasone Intravitreal Implant for Diabetic Macular Edema: Indications for a PRN Regimen of Treatment , 2015, European journal of ophthalmology.

[20]  S. Whitcup,et al.  Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. , 2014, Ophthalmology.

[21]  Ningli Wang,et al.  Diabetic macular edema: new concepts in patho-physiology and treatment , 2014, Cell & Bioscience.

[22]  M. Postorino,et al.  Dexamethasone Intravitreal Implant for Treatment of Patients with Persistent Diabetic Macular Edema , 2013, Ophthalmologica.

[23]  S. Gupta,et al.  Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. , 2013, Ophthalmology.

[24]  T. Peto,et al.  A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. , 2012, Archives of ophthalmology.

[25]  Quan Dong Nguyen,et al.  Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. , 2012, Ophthalmology.

[26]  M. Blumenkranz,et al.  Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. , 2011, Ophthalmology.

[27]  S. Whitcup,et al.  Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. , 2011, Investigative ophthalmology & visual science.

[28]  H. Tabandeh,et al.  DEXAMETHASONE INTRAVITREAL IMPLANT FOR TREATMENT OF DIABETIC MACULAR EDEMA IN VITRECTOMIZED PATIENTS , 2011, Retina.

[29]  Jennifer K. Sun,et al.  Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. , 2011, Ophthalmology.

[30]  Hyewon Chung,et al.  Association between photoreceptor integrity and visual outcome in diabetic macular edema , 2011, Graefe's Archive for Clinical and Experimental Ophthalmology.

[31]  Simon P. Harding,et al.  Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study) , 2010, Diabetes Care.

[32]  Mark Kester,et al.  Diabetic Retinopathy , 2006, Diabetes.

[33]  T. Lawrence,et al.  Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1 , 2006, The Journal of experimental medicine.

[34]  P. J. Barnes,et al.  Corticosteroid effects on cell signalling , 2006, European Respiratory Journal.

[35]  Peter Wiedemann,et al.  Pathomechanisms of Cystoid Macular Edema , 2004, Ophthalmic Research.

[36]  L. Aiello,et al.  Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. , 1998, Diabetes.

[37]  PHOTOCOAGULATION FOR DIABETIC MACULAR EDEMA: EARLY TREATMENT DIABETIC RETINOPATHY STUDY REPORT NO. 4 , 1987, International ophthalmology clinics.